Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

NCT00086203 is registered in ClinicalTrials.gov with Point Therapeutics as lead sponsor.

NCT NCT00086203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Point Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
September 30, 2007
Enrollment
Not reported
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia